Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the
treatment of coronary artery disease. Results from SPIRIT PRIME will be used to support the regulatory filing for XIENCE PRIME in the United States.
Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer's disease. Current therapies for Alzheimer's disease can improve symptoms, but do not affect the progression of the disease.
Eli Lilly and Company Announces New Drug Discovery Initiative
- Details
- Category: Eli Lilly and Company
Goal is to foster open collaboration between Lilly and global laboratory researchers
Alzheimer's disease. Cancer. Diabetes. Osteoporosis.
These are the diseases for which Eli Lilly and Company will be engaging researchers from around the world in a new and unique drug discovery initiative.
Alzheimer's disease. Cancer. Diabetes. Osteoporosis.
These are the diseases for which Eli Lilly and Company will be engaging researchers from around the world in a new and unique drug discovery initiative.
Novartis demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine
- Details
- Category: Novartis
Novartis has successfully completed the production of the first batch of influenza A(H1N1) vaccine, weeks ahead of expectations. Cell-based manufacturing technology[1] allows vaccine production to be initiated once a pandemic virus strain is identified without the need to adapt the virus strain to grow in eggs, as with traditional vaccine technologies. This advance has cut weeks off the time required to begin vaccine production.
Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that the European Commission has approved Renvela® (sevelamer carbonate) for the control of serum phosphorus in patients with chronic kidney disease (CKD). The approval includes patients not on dialysis with serum phosphorus levels ≥ 1.78 mmol/L (5.5 mg/dL), and covers both the tablet and powder formulations.
Abbott Announces Launch of Next-Generation Embolic Protection System
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced the launch of the sixth-generation Emboshield NAV6(TM) Embolic Protection System for use in carotid artery stenting procedures. Carotid artery stenting provides a minimally invasive treatment alternative to conventional open carotid artery surgery for patients who are at high risk for surgery.
Favourable Vote from FDA Advisory Committee on Seroquel Paediatric Applications
- Details
- Category: AstraZeneca
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee conducted a review of the efficacy and safety of supplemental new drug applications (sNDAs) for SEROQUEL (quetiapine fumarate) proposed for the acute treatment of schizophrenia in adolescents (13-17 years of age), and the acute treatment of bipolar mania in children and adolescents (10-17 years of age).
More Pharma News ...
- Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe
- GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China
- Sanofi-aventis to strengthen Insulin Production Capacities
- Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust
- Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)
- World Health Organization grants Global Prequalification to GSK's Rotarix⢠vaccine
- New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure